Jump to content

Stefan Karlsson (professor)

From Wikipedia, the free encyclopedia
(Redirected from Stefan Karlsson (Professor))
This article is about the professor. For other people of the same name, see Stefan Karlsson.

Stefan Karlsson (born Iceland, 31 May 1950) is a Professor of Molecular Medicine and Gene Therapy at the Lund Stem Cell Center, in the Department of Laboratory Medicine, Lund University, Sweden.[1] He is recognized for significant contributions to the fields of gene therapy and hematopoietic stem cell biology and in 2009 was awarded the Tobias Prize[2] by The Royal Swedish Academy of Sciences.

Career

[edit]

Karlsson's field of research is the regulation of hematopoietic stem cells and development of stem cell expansion protocols and gene therapy. He performed postdoctoral studies with Professor Arthur W. Nienhuis (1983-1986) at the National Heart Lung and Blood Institute (NHLBI) at the National Institutes of Health (NIH), Bethesda Maryland, where he received a Fogarty International Research Collaboration Award. He served as Chief of the Molecular and Medical Genetics Section, Developmental and Metabolic Neurology Branch (DMNB), National Institute for Neurological Disorders and Stroke (NINDS), NIH, 1988-1996. In 1995 he was recruited as a full professor to Lund University, Sweden, where he founded the Division of Molecular Medicine and Gene Therapy[3] and has been head of this division for twenty years.[4] He is also a founding and current member of the Lund Stem Cell Center,[5] since 2003, and director of the Hemato-Linné Strategic Research Environment[6] (2006-2016) funded through a 10-year Linnaeus grant from the Swedish Research Council.[7] Dr. Karlsson also holds a consultant physician position at Skåne University Hospital,[8] Sweden.

Research

[edit]

Karlsson's early research focused on retroviral vector based gene correction of hematopoietic cells from monogenetic disorders, such as Gaucher’s disease[9] and hemoglobinopathies.[10] The results of these studies led to the first gene therapy clinical trial for the treatment of Gaucher’s disease (1995).[11] He has also developed lentiviral vectors for gene correction of hematopoietic stem cells,[12] and more recently developed preclinical gene therapy models for Gaucher’s disease[13] and Diamond Blackfan anemia.[14] An equal component of his research has been in the field of hematopoietic stem cell biology, where Dr. Karlsson focused on studying the mechanisms of hematopoietic stem cell expansion and maintenance with major contributions to understanding the role of Tgf-beta[15] and more recently Cripto.[16]

Selected awards and honors

[edit]

References

[edit]
  1. ^ "Lund University, Stem Cell Center, Sweden: Stefan Karlsson".
  2. ^ "Tobias laureates". The Royal Swedish Academy of Sciences. Archived from the original on 2016-10-31. Retrieved 2015-06-02.
  3. ^ "Division of Molecular Medicine and Gene Therapy, Lund University, Sweden". Archived from the original on 2017-09-10. Retrieved 2015-05-13.
  4. ^ "Symposium in Honor of Stefan Karlsson: Founder of Division of Molecular Medicine and Gene Therapy".
  5. ^ "Lund Stem Cell Center".
  6. ^ "Hemato-Linné Strategic Research Environment: Lund University, Sweden".
  7. ^ "Swedish Research Counsel: Hemato-Linné Environment coordinated by Stefan Karlsson".
  8. ^ "Skåne University Hospital".
  9. ^ Fink, JK; Correll, PH; Perry, LK; Brady, RO; Karlsson, S (March 1990). "Correction of glucocerebrosidase deficiency after retroviral-mediated gene transfer into hematopoietic progenitor cells from patients with Gaucher disease". Proceedings of the National Academy of Sciences of the United States of America. 87 (6): 2334–8. doi:10.1073/pnas.87.6.2334. PMC 53681. PMID 2315324.
  10. ^ Karlsson, S; Bodine, DM; Perry, L; Papayannopoulou, T; Nienhuis, AW (August 1988). "Expression of the human beta-globin gene following retroviral-mediated transfer into multipotential hematopoietic progenitors of mice". Proceedings of the National Academy of Sciences of the United States of America. 85 (16): 6062–6. doi:10.1073/pnas.85.16.6062. PMC 281905. PMID 3413076.
  11. ^ Dunbar, CE; Kohn, DB; Schiffmann, R; Barton, NW; Nolta, JA; Esplin, JA; Pensiero, M; Long, Z; Lockey, C; Emmons, RV; Csik, S; Leitman, S; Krebs, CB; Carter, C; Brady, RO; Karlsson, S (20 November 1998). "Retroviral transfer of the glucocerebrosidase gene into CD34+ cells from patients with Gaucher disease: in vivo detection of transduced cells without myeloablation". Human Gene Therapy. 9 (17): 2629–40. doi:10.1089/hum.1998.9.17-2629. PMID 9853529.
  12. ^ Woods, NB; Fahlman, C; Mikkola, H; Hamaguchi, I; Olsson, K; Zufferey, R; Jacobsen, SE; Trono, D; Karlsson, S (1 December 2000). "Lentiviral gene transfer into primary and secondary NOD/SCID repopulating cells". Blood. 96 (12): 3725–33. doi:10.1182/blood.V96.12.3725.h8003725_3725_3733. PMID 11090053.
  13. ^ Enquist, IB; Nilsson, E; Ooka, A; Månsson, JE; Olsson, K; Ehinger, M; Brady, RO; Richter, J; Karlsson, S (12 September 2006). "Effective cell and gene therapy in a murine model of Gaucher disease". Proceedings of the National Academy of Sciences of the United States of America. 103 (37): 13819–24. doi:10.1073/pnas.0606016103. PMC 1564262. PMID 16954197.
  14. ^ Jaako, P; Flygare, J; Olsson, K; Quere, R; Ehinger, M; Henson, A; Ellis, S; Schambach, A; Baum, C; Richter, J; Larsson, J; Bryder, D; Karlsson, S (1 December 2011). "Mice with ribosomal protein S19 deficiency develop bone marrow failure and symptoms like patients with Diamond-Blackfan anemia". Blood. 118 (23): 6087–96. doi:10.1182/blood-2011-08-371963. PMID 21989989.
  15. ^ Kulkarni, AB; Huh, CG; Becker, D; Geiser, A; Lyght, M; Flanders, KC; Roberts, AB; Sporn, MB; Ward, JM; Karlsson, S (15 January 1993). "Transforming growth factor beta 1 null mutation in mice causes excessive inflammatory response and early death". Proceedings of the National Academy of Sciences of the United States of America. 90 (2): 770–4. doi:10.1073/pnas.90.2.770. PMC 45747. PMID 8421714.
  16. ^ Miharada, K; Karlsson, G; Rehn, M; Rörby, E; Siva, K; Cammenga, J; Karlsson, S (4 October 2011). "Cripto regulates hematopoietic stem cells as a hypoxic-niche-related factor through cell surface receptor GRP78". Cell Stem Cell. 9 (4): 330–44. doi:10.1016/j.stem.2011.07.016. PMID 21982233.
  17. ^ "Past Presidents of International Society for Experimental Hematology" (PDF).
  18. ^ "Tobias Prize Laureates: The Royal Swedish Academy of Sciences". Archived from the original on 2016-10-31. Retrieved 2015-06-02.
  19. ^ "Wallenberg Foundation: Excellence in Swedish Research awards 2014".
Retrieved from "https://wiki.riteme.site/w/index.php?title=Stefan_Karlsson_(professor)&oldid=1214265772"